Correction to: Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor c-terminal binding protein-1 (Circulation (2016) 134 (1105-1121) DOI: 10.1161/CIRCULATIONAHA.116.023171);Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1

Circulation

Volumn 134, Issue 15, 2016, Pages 1105-1121

  Li, Min ^a   Riddle, Suzette ^a   Zhang, Hui ^a   D'Alessandro, Angelo ^b   Flockton, Amanda ^a   Serkova, Natalie J ^c   Hansen, Kirk C ^b   Moldvan, Radu ^b   McKeon, B Alexandre ^a   Frid, Maria ^a   Kumar, Sushil ^a   Li, Hong ^c   Liu, Hongbing ^c   Cánovas, Angela ^g   Medrano, Juan F ^h   Thomas, Milton G ⁱ   Iloska, Dijana ^f   Plecitá Hlavatá, Lydie ^e   Ježek, Petr ^e   Pullamsetti, Soni ^f   Fini, Mehdi A ^a   El Kasmi, Karim C ^d   Zhang, QingHong ^c   Stenmark, Kurt R ^a   more..

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d University of Colorado Denver and Children s Hospital Colorado   (United States)

^e INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^f MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^g UNIVERSITY OF GUELPH   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

cell proliferation; fibroblasts; glycolysis; hypertension, pulmonary; metabolism

Indexed keywords

4 METHYLTHIO 2 OXOBUTYRIC ACID; BINDING PROTEIN; COREPRESSOR C TERMINAL BINDING PROTEIN 1; COREPRESSOR PROTEIN; HEME OXYGENASE 1; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; C-TERMINAL BINDING PROTEIN; DNA BINDING PROTEIN;

AEROBIC GLYCOLYSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; FIBROBLAST; FLUORESCENCE; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MACROPHAGE; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NEWBORN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; STEADY STATE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADVENTITIA; ANIMAL; CELL CULTURE; GENETICS; METABOLISM; PATHOLOGY;

ADVENTITIA; ALCOHOL OXIDOREDUCTASES; ANIMALS; CELLS, CULTURED; DNA-BINDING PROTEINS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; MICE; PHENOTYPE;

EID: 84986216601     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000647     Document Type: Erratum

References (53)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(suppl):D34-D41. doi: 10.1016/j.jacc.2013.10.029.
2. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest. 2012;141:210-221. doi: 10.1378/ chest.11-0793.
3. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032. doi: 10.1152/ajplung.00217.2009.
4. Das M, Burns N, Wilson SJ, Zawada WM, Stenmark KR. Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia. Cardiovasc Res. 2008;78:440-448. doi: 10.1093/cvr/cvn014.
5. El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL, Frid MG, Li M, Pullamsetti SS, Savai R, Nagel MA, Fini MA, Graham BB, Tuder RM, Friedman JE, Eltzschig HK, Sokol RJ, Stenmark KR. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol. 2014;193:597-609. doi: 10.4049/jimmunol.1303048.
6. Krick S, Hänze J, Eul B, Savai R, Seay U, Grimminger F, Lohmeyer J, Klepetko W, Seeger W, Rose F. Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF-1alpha and an autocrine angiotensin system. FASEB J. 2005;19:857-859. doi: 10.1096/fj.04-2890fje.
7. Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, Strassheim D, Meyrick B, Yeager ME, Flockton AR, McKeon BA, Lemon DD, Horn TR, Anwar A, Barajas C, Stenmark KR. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol. 2011;187:2711-2722. doi: 10.4049/jimmunol.1100479.
8. Panzhinskiy E, Zawada WM, Stenmark KR, Das M. Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFβ receptor-JNK1 signalling. Cardiovasc Res. 2012;95:356-365. doi: 10.1093/cvr/cvs194.
9. Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res. 2014;114:67-78. doi: 10.1161/CIRCRESAHA.114.301633.
10. Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, Huertas A, Humbert M, Montani D. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev. 2013;22:543-551. doi: 10.1183/09059180.00007513.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. doi: 10.1016/j.cell.2011. 02.013.
12. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res. 2014;115:148-164. doi: 10.1161/ CIRCRESAHA.115.301130.
13. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033. doi: 10.1126/science.1160809.
14. Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, Tomasi G, Nguyen QD, Aboagye EO, El-Bahrawy MA, Barnes G, Howard LS, Gibbs JS, Gsell W, He JG, Wilkins MR. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation. 2013;128:1214-1224. doi: 10.1161/CIRCULATIONAHA. 113.004136.
15. Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res. 2009;69:731-734. doi: 10.1158/0008-5472.CAN-08-3349.
16. Peña C, García JM, García V, Silva J, Domínguez G, Rodríguez R, Maximiano C, García de Herreros A, Muñoz A, Bonilla F. The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int J Cancer. 2006;119:2098-2104. doi: 10.1002/ijc.22083.
17. Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, Siddiqui J, Dhanasekaran SM, Nyati MK, Pienta KJ, Palanisamy N, Kunju LP, Rubin MA, Chinnaiyan AM, Varambally S. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia. 2012;14:905-914.
18. Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, Raab R, Olopade OI, Gardner K. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun. 2013;4:1449. doi: 10.1038/ncomms2438.
19. Grooteclaes M, Deveraux Q, Hildebrand J, Zhang Q, Goodman RH, Frisch SM. C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci U S A. 2003;100:4568-4573. doi: 10.1073/pnas.0830998100.
20. Zhang G, Yan Y, Kang L, Cao Q, Ke K, Wu X, Gao Y, Hang Q, Li C, Zhu L, Yuan Q, Wu Q, Cheng C. Involvement of CtBP2 in LPSinduced microglial activation. J Mol Histol. 2012;43:327-334. doi: 10.1007/s10735-012-9399-x.
21. Byun JS, Gardner K. C-terminal binding protein: a molecular link between metabolic imbalance and epigenetic regulation in breast cancer. Int J Cell Biol. 2013;2013:647975. doi: 10.1155/2013/647975.
22. Fjeld CC, Birdsong WT, Goodman RH. Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci U S A. 2003;100:9202-9207. doi: 10.1073/pnas.1633591100.
23. Zhang Q, Piston DW, Goodman RH. Regulation of corepressor function by nuclear NADH. Science. 2002;295:1895-1897. doi: 10.1126/science.1069300.
24. Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D, Whalen GF, Lyle S, Schiffer CA, Grossman SR. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle. 2010;9:3740-3750. doi: 10.4161/cc.9.18.12936.
25. NCBI, Genomes & Maps, Genome. http://www.ncbi.nlm.nih.gov/genome/?term=bos+taurus. Accessed September 20, 2016.
26. Williamson DH, Lund P, Krebs HA. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J. 1967;103:514-527.
27. GraphPad, Software, Inc. GraphPad Software. www.graphpad.com. Accessed September 20, 2016.
28. Plecitá-Hlavatá L, Tauber J, Li M, Zhang H, Flockton AR, Pullamsetti SS, Chelladurai P, D'Alessandro A, El Kasmi KC, Ježek P, Stenmark KR. Constitutive reprogramming of fibroblast mitochondrial metabolism in pulmonary hypertension. Am J Respir Cell Mol Biol. 2016;55:47-57. doi: 10.1165/rcmb.2015-0142OC.
29. Zhang Q, Yoshimatsu Y, Hildebrand J, Frisch SM, Goodman RH. Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP. Cell. 2003;115:177-186.
30. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25:771-784. doi: 10.1038/cr.2015.68.
31. Stenmark KR, Tuder RM, El Kasmi KC. Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension. J Appl Physiol (1985). 2015;119:1164-1172. doi: 10.1152/japplphysiol. 00283.2015.
32. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A. 2001;98:8798-8803. doi: 10.1073/pnas.161272598.
33. Palsson-McDermott EM, O'Neill LA. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays. 2013;35:965-973. doi: 10.1002/bies.201300084.
34. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch MW, Quinn SR, Domingo-Fernandez R, Johnston DG, Jiang JK, Jiang JK, Israelsen WJ, Keane J, Thomas C, Clish C, Vander Heiden M, Vanden Heiden M, Xavier RJ, O'Neill LA. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015;21:65-80. doi: 10.1016/j.cmet.2014.12.005.
35. Belhaj A, Dewachter L, Kerbaul F, Brimioulle S, Dewachter C, Naeije R, Rondelet B. Heme oxygenase-1 and inflammation in experimental right ventricular failure on prolonged overcirculationinduced pulmonary hypertension. PLoS One. 2013;8:e69470. doi: 10.1371/journal.pone.0069470.
36. Constantin M, Choi AJ, Cloonan SM, Ryter SW. Therapeutic potential of heme oxygenase-1/carbon monoxide in lung disease. Int J Hypertens. 2012;2012:859235. doi: 10.1155/2012/859235.
37. Liang OD, Mitsialis SA, Chang MS, Vergadi E, Lee C, Aslam M, Fernandez-Gonzalez A, Liu X, Baveja R, Kourembanas S. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells. 2011;29:99-107. doi: 10.1002/ stem.548.
38. Vergadi E, Chang MS, Lee C, Liang OD, Liu X, Fernandez-Gonzalez A, Mitsialis SA, Kourembanas S. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation. 2011;123:1986-1995. doi: 10.1161/CIRCULATIONAHA. 110.978627.
39. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res. 2007;8:15. doi: 10.1186/1465-9921-8-15.
40. Hsia HC, Schwarzbauer JE. Meet the tenascins: multifunctional and mysterious. J Biol Chem. 2005;280:26641-26644. doi: 10.1074/jbc.R500005200.
41. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(suppl):D4-12. doi: 10.1016/j.jacc.2013.10.025.
42. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10:267-277. doi: 10.1038/nrc2817.
43. Kim JH, Cho EJ, Kim ST, Youn HD. CtBP represses p300-mediated transcriptional activation by direct association with its bromodomain. Nat Struct Mol Biol. 2005;12:423-428. doi: 10.1038/ nsmb924.
44. Mirnezami AH, Campbell SJ, Darley M, Primrose JN, Johnson PW, Blaydes JP. Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Curr Biol. 2003;13:1234-1239.
45. Wu X, Chang MS, Mitsialis SA, Kourembanas S. Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1. Circ Res. 2006;99:240-247. doi: 10.1161/01. RES.0000237021.65103.24.
46. Abraham NG, Levere RD, Lin JH, Beru N, Hermine O, Goldwasser E. Co-regulation of heme oxygenase and erythropoietin genes. J Cell Biochem. 1991;47:43-48. doi: 10.1002/jcb.240470106.
47. Morita T, Mitsialis SA, Koike H, Liu Y, Kourembanas S. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem. 1997;272:32804-32809.
48. Morita T, Perrella MA, Lee ME, Kourembanas S. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc Natl Acad Sci U S A. 1995;92:1475-1479.
49. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, Lee ME. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest. 1999;103:R23-R29. doi: 10.1172/JCI6163.
50. Di LJ, Fernandez AG, De Siervi A, Longo DL, Gardner K. Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat Struct Mol Biol. 2010;17:1406-1413. doi: 10.1038/nsmb.1941.
51. Wang L, Zhou H, Wang Y, Cui G, Di LJ. CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4. Cell Death Dis. 2015;6:e1620. doi: 10.1038/cddis.2014.587.
52. Blevins MA, Kouznetsova J, Krueger AB, King R, Griner LM, Hu X, Southall N, Marugan JJ, Zhang Q, Ferrer M, Zhao R. Small molecule, NSC95397, inhibits the CtBP1-protein partner interaction and CtBP1-mediated transcriptional repression. J Biomol Screen. 2015;20:663-672. doi: 10.1177/1087057114561400.
53. Yang Y, Yang WS, Yu T, Yi YS, Park JG, Jeong D, Kim JH, Oh JS, Yoon K, Kim JH, Cho JY. Novel anti-inflammatory function of NSC95397 by the suppression of multiple kinases. Biochem Pharmacol. 2014;88:201-215. doi: 10.1016/j.bcp.2014.01.022.